Sun Pharma Advanced Research Company (SPARC) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
4 Aug, 2025Executive summary
Board approved unaudited standalone and consolidated financial results for Q1 ended June 30, 2025.
Financial statements reviewed by statutory auditors with no material misstatements identified.
Financial highlights
Consolidated revenue from operations was ₹964 lakhs, down from ₹1,681 lakhs year-over-year.
Consolidated net loss for Q1 FY26 was ₹5,187 lakhs, improved from ₹9,590 lakhs loss in Q1 FY25.
Standalone net loss for Q1 FY26 was ₹5,203 lakhs, compared to ₹9,684 lakhs loss in Q1 FY25.
Basic and diluted EPS (consolidated) for Q1 FY26 was (₹1.60), versus (₹2.96) in Q1 FY25.
Outlook and guidance
Company continues as a going concern based on support letter from promoter group entity.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Sun Pharma Advanced Research Company
- Q3 FY26 net loss widened, revenue declined, and a US FDA PRV was granted for Sezaby®.SPARC
Q3 25/269 Feb 2026 - Oncology and immunology assets prioritized, with key cash catalysts and clinical milestones ahead.SPARCStatus Update10 Jan 2026
- Lead programs advance in oncology and immunology, backed by partnerships and cost savings.SPARCR&D Day 20268 Jan 2026
- Net loss persists amid declining revenue, with operations supported by promoter group backing.SPARCQ1 24/2521 Nov 2025
- Net loss deepened in Q2 FY25 amid falling revenues and persistent high expenses.SPARCQ2 24/2521 Nov 2025
- Losses narrowed but remain significant; promoter support continues to underpin operations.SPARCQ2 25/2610 Nov 2025
- SPARC narrowed its annual loss and plans to raise up to Rs. 1,800 crores for future growth.SPARCQ4 24/256 Jun 2025
- Q3 FY25 results reflect ongoing losses, R&D focus, and a new subsidiary for future growth.SPARCQ3 24/256 Jun 2025